The negative reaction in Disc Medicine's stock price likely stems from investor disappointment or concerns over the topline results of the Phase 2 AURORA study of bitopertin in EPP patients. Such clinical trial outcomes are critical for biotech companies, as they can significantly influence the company's future revenue potential and growth prospects.